B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

CTSL

MOLECULAR TARGET

cathepsin L

UniProt: P07711NCBI Gene: 151418 compounds

CTSL (cathepsin L) is targeted by 18 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting CTSL

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1mg 1324.66105
2pepstatin4.3073
3e 644.1160
4telaprevir4.0959
5boceprevir4.0959
6k 7773.4731
7leupeptin3.4029
8camostat3.0420
9echinatin2.8917
10calpeptin2.8316
11aloxistatin2.7715
12odanacatib2.7114
13allicin2.7114
14pf 008352312.7114
15balicatib2.309
16gallinamide a2.309
17cyano pyrrolidine1.956
18Triamcinolone0.691

About CTSL as a Drug Target

CTSL (cathepsin L) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 18 compounds with documented CTSL interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

CTSL inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.